Toxicogenomics of drug induced liver injury – from mechanistic understanding to early prediction.

References

• Bell CC, Dankers ACA, Lauschke VM, Sison-Young R, Jenkins R, Rowe C, Goldring CE, Park K, Regan SL, Walker T, et al. 2018. Comparison of hepatic 2D sandwich cultures and 3D spheroids for long-term toxicity applications: a multicenter study. Toxicol Sci. 162(2):655–666.
   PubMed Web of Science ®Google Scholar
• Bell CC, Lauschke VM, Vorrink SU, Palmgren H, Duffin R, Andersson TB, Ingelman-Sundberg M. 2017. Transcriptional, functional, and mechanistic comparisons of stem cell-derived hepatocytes, HepaRG cells, and three-dimensional human hepatocyte spheroids as predictive in vitro systems for drug-induced liver injury. Drug Metab Dispos. 45(4):419–429.
   PubMed Web of Science ®Google Scholar
• Bell L, Chalasani N. 2009. Epidemiology of idiosyncratic drug-induced liver injury. Semin Liver Dis. 29(4):337–347.
   PubMed Web of Science ®Google Scholar
• Björnsson E. 2010. Review article: drug-induced liver injury in clinical practice. Aliment Pharmacol Ther. 32(1):3–13.
   PubMed Web of Science ®Google Scholar
• Bjornsson ES, Bergmann OM, Björnsson HK, Kvaran RB, Olafsson S. 2013. Incidence, presentation, and outcomes in patients with drug-induced liver injury in the general population of iceland. Gastroenterology. 144(7):1419–1425.
   PubMed Web of Science ®Google Scholar
• Braeuning A, et al. 2020. RNA-protein correlation of liver toxicity markers in HepaRG cells. EXCLI J. 19:135–153.
   PubMed Web of Science ®Google Scholar
• Choudhury Y, Toh YC, Xing J, Qu Y, Poh J, Li H, Tan HS, Kanesvaran R, Yu H, Tan M-H, et al. 2017. Patient-specific hepatocyte-like cells derived from induced pluripotent stem cells model pazopanib-mediated hepatotoxicity. Sci Rep. 7:46391.
   PubMed Web of Science ®Google Scholar
• Chu X, Bleasby K, Evers R. 2013. Species differences in drug transporters and implications for translating preclinical findings to humans. Expert Opin Drug Metab Toxicol. 9(3):237–252.
   PubMed Web of Science ®Google Scholar
• Cook D, Brown D, Alexander R, March R, Morgan P, Satterthwaite G, Pangalos MN. 2014. Lessons learned from the fate of AstraZeneca’s drug pipeline: a five-dimensional framework. Nat Rev Drug Discov. 13(6):419–431.
   PubMed Web of Science ®Google Scholar
• Copple IM, den Hollander W, Callegaro G, Mutter FE, Maggs JL, Schofield AL, Rainbow L, Fang Y, Sutherland JJ, Ellis EC, et al. 2019. Characterisation of the NRF2 transcriptional network and its response to chemical insult in primary human hepatocytes: implications for prediction of drug-induced liver injury. Arch Toxicol. 93(2):385–399.
   PubMed Web of Science ®Google Scholar
• de Abajo FJ, Montero D, Madurga M, García Rodríguez LA. 2004. Acute and clinically relevant drug-induced liver injury: a population based case-control study. Br J Clin Pharmacol. 58(1):71–80.
   PubMed Web of Science ®Google Scholar
• Deferme L, Wolters J, Claessen S, Briedé J, Kleinjans J. 2015. Oxidative stress mechanisms do not discriminate between genotoxic and nongenotoxic liver carcinogens. Chem Res Toxicol. 28(8):1636–1646.
   PubMed Web of Science ®Google Scholar
• Fredriksson L, Wink S, Herpers B, Benedetti G, Hadi M, de Bont H, Groothuis G, Luijten M, Danen E, de Graauw M, et al. 2014. Drug-induced endoplasmic reticulum and oxidative stress responses independently sensitize toward TNFα-mediated hepatotoxicity. Toxicol Sci. 140(1):144–159.
   PubMed Web of Science ®Google Scholar
• Gerets HHJ, Tilmant K, Gerin B, Chanteux H, Depelchin BO, Dhalluin S, Atienzar FA. 2012. Characterization of primary human hepatocytes, HepG2 cells, and HepaRG cells at the mRNA level and CYP activity in response to inducers and their predictivity for the detection of human hepatotoxins. Cell Biol Toxicol. 28(2):69–87.
   PubMed Web of Science ®Google Scholar
• Goetz AK, Dix DJ. 2009. Toxicogenomic effects common to triazole antifungals and conserved between rats and humans. Toxicol Appl Pharmacol. 238(1):80–89.
   PubMed Web of Science ®Google Scholar
• Hart SN, Li Y, Nakamoto K, Subileau E-a, Steen D, Zhong X-b. 2010. A comparison of whole genome gene expression profiles of HepaRG cells and HepG2 cells to primary human hepatocytes and human liver tissues. Drug Metab Dispos. 38(6):988–994.
   PubMed Web of Science ®Google Scholar
• Jennen D, Ruiz-Aracama A, Magkoufopoulou C, Peijnenburg A, Lommen A, van Delft J, Kleinjans J. 2011. Integrating transcriptomics and metabonomics to unravel modes-of-action of 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) in HepG2 cells. BMC Syst Biol. 5:139
   PubMed Web of Science ®Google Scholar
• Jennen DGJ, Magkoufopoulou C, Ketelslegers HB, van Herwijnen MHM, Kleinjans JCS, van Delft JHM. 2010. Comparison of HepG2 and HepaRG by whole-genome gene expression analysis for the purpose of chemical hazard identification. Toxicol Sci. 115(1):66–79.
   PubMed Web of Science ®Google Scholar
• Jiang J, Briedé JJ, Jennen DGJ, Van Summeren A, Saritas-Brauers K, Schaart G, Kleinjans JCS, de Kok TMCM. 2015. Increased mitochondrial ROS formation by acetaminophen in human hepatic cells is associated with gene expression changes suggesting disruption of the mitochondrial electron transport chain. Toxicol Lett. 234(2):139–150.
   PubMed Web of Science ®Google Scholar
• Khetani SR, Kanchagar C, Ukairo O, Krzyzewski S, Moore A, Shi J, Aoyama S, Aleo M, Will Y. 2013. Use of micropatterned cocultures to detect compounds that cause drug-induced liver injury in humans. Toxicol Sci. 132(1):107–117.
   PubMed Web of Science ®Google Scholar
• Koido M, Kawakami E, Fukumura J, Noguchi Y, Ohori M, Nio Y, Nicoletti P, Aithal GP, Daly AK, Watkins PB, et al. 2020. Polygenic architecture informs potential vulnerability to drug-induced liver injury. Nat Med. 26(10):1541–1548.
   PubMed Web of Science ®Google Scholar
• Kuna L, Bozic I, Kizivat T, Bojanic K, Mrso M, Kralj E, Smolic R, Wu GY, Smolic M. 2018. Models of Drug Induced Liver Injury (DILI) – current issues and future perspectives. Curr Drug Metab. 19(10):830–838.
   PubMed Web of Science ®Google Scholar
• Larrey D. 2002. Epidemiology and individual susceptibility to adverse drug reactions affecting the liver. Semin Liver Dis. 22(2):145–155.
   PubMed Web of Science ®Google Scholar
• Lauschke VM, Hendriks DFG, Bell CC, Andersson TB, Ingelman-Sundberg M. 2016. Novel 3D culture systems for studies of human liver function and assessments of the hepatotoxicity of drugs and drug candidates. Chem Res Toxicol. 29(12):1936–1955.
   PubMed Web of Science ®Google Scholar
• Lauschke VM, Shafagh RZ, Hendriks DFG, Ingelman-Sundberg M. 2019. 3D primary hepatocyte culture systems for analyses of liver diseases, drug metabolism, and toxicity: emerging culture paradigms and applications. Biotechnol J. 14(7):e1800347.
   PubMed Web of Science ®Google Scholar
• Lauschke VM, Vorrink SU, Moro SML, Rezayee F, Nordling Å, Hendriks DFG, Bell CC, Sison-Young R, Park BK, Goldring CE, et al. 2016. Massive rearrangements of cellular MicroRNA signatures are key drivers of hepatocyte dedifferentiation. Hepatology. 64(5):1743–1756.
   PubMed Web of Science ®Google Scholar
• Liguori MJ, Anderson MG, Bukofzer S, McKim J, Pregenzer JF, Retief J, Spear BB, Waring JF. 2005. Microarray analysis in human hepatocytes suggests a mechanism for hepatotoxicity induced by trovafloxacin. Hepatology. 41(1):177–186.
   PubMed Web of Science ®Google Scholar
• Liguori MJ, Blomme EAG, Waring JF. 2008. Trovafloxacin-induced gene expression changes in liver-derived in vitro systems: comparison of primary human hepatocytes to HepG2 cells. Drug Metab Dispos. 36(2):223–233.
   PubMed Web of Science ®Google Scholar
• Limonciel A, Ates G, Carta G, Wilmes A, Watzele M, Shepard PJ, VanSteenhouse HC, Seligmann B, Yeakley JM, van de Water B, et al. 2018. Comparison of base-line and chemical-induced transcriptomic responses in HepaRG and RPTEC/TERT1 cells using TempO-Seq. Arch Toxicol. 92(8):2517–2531.
   PubMed Web of Science ®Google Scholar
• Lin C, Khetani SR. 2016. Advances in engineered liver models for investigating drug-induced liver injury. BioMed Res Int . 2016:1–20.
   Web of Science ®Google Scholar
• Magkoufopoulou C, Claessen SMH, Tsamou M, Jennen DGJ, Kleinjans JCS, van Delft JHM. 2012. A transcriptomics-based in vitro assay for predicting chemical genotoxicity in vivo. Carcinogenesis. 33(7):1421–1429.
   PubMed Web of Science ®Google Scholar
• Martignoni M, Groothuis GMM, de Kanter R. 2006. Species differences between mouse, rat, dog, monkey and human CYP-mediated drug metabolism, inhibition and induction. Expert Opin Drug Metab Toxicol. 2(6):875–894.
   PubMed Web of Science ®Google Scholar
• Mesnage R, Biserni M, Balu S, Frainay C, Poupin N, Jourdan F, Wozniak E, Xenakis T, Mein CA, Antoniou MN, et al. 2018. Integrated transcriptomics and metabolomics reveal signatures of lipid metabolism dysregulation in HepaRG liver cells exposed to PCB 126. Arch Toxicol. 92(8):2533–2547.
   PubMed Web of Science ®Google Scholar
• Messina A, Luce E, Hussein M, Dubart-Kupperschmitt A. 2020. Pluripotent-stem-cell-derived hepatic cells: hepatocytes and organoids for liver therapy and regeneration. Cells. 9(2):420.
   PubMed Web of Science ®Google Scholar
• Navarro VJ, Khan I, Björnsson E, Seeff LB, Serrano J, Hoofnagle JH. 2017. Liver injury from herbal and dietary supplements. Hepatology. 65(1):363–373.
   PubMed Web of Science ®Google Scholar
• Navarro VJ, Senior JR. 2006. Drug-related hepatotoxicity. N Engl J Med. 354(7):731–739.
   PubMed Web of Science ®Google Scholar
• Onakpoya IJ, Heneghan CJ, Aronson JK. 2016. Post-marketing withdrawal of 462 medicinal products because of adverse drug reactions: a systematic review of the world literature. BMC Med. 14:10–11.
   PubMed Web of Science ®Google Scholar
• Ostapowicz G, Fontana RJ, Schiødt FV, Larson A, Davern TJ, Han SHB, McCashland TM, Shakil AO, Hay JE, Hynan L, et al. 2002. Results of a prospective study of acute liver failure at 17 tertiary care centers in the United States. Ann Intern Med. 137(12):947–954.
   PubMed Web of Science ®Google Scholar
• Parent R, Marion M-J, Furio L, Trepo C, Petit M-A. 2004. Origin and characterization of a human bipotent liver progenitor cell line. Gastroenterology. 126(4):1147–1156.
   PubMed Web of Science ®Google Scholar
• Proctor WR, Foster AJ, Vogt J, Summers C, Middleton B, Pilling MA, Shienson D, Kijanska M, Ströbel S, Kelm JM, et al. 2017. Utility of spherical human liver microtissues for prediction of clinical drug-induced liver injury. Arch Toxicol. 91(8):2849–2863.
   PubMed Web of Science ®Google Scholar
• Ramirez T, Strigun A, Verlohner A, Huener H-A, Peter E, Herold M, Bordag N, Mellert W, Walk T, Spitzer M, et al. 2018. Prediction of liver toxicity and mode of action using metabolomics in vitro in HepG2 cells. Arch Toxicol. 92(2):893–906.
   PubMed Web of Science ®Google Scholar
• Rieswijk L, Claessen SMH, Bekers O, van Herwijnen M, Theunissen DHJ, Jennen DGJ, de Kok TMCM, Kleinjans JCS, van Breda SGJ. 2016. Aflatoxin B1 induces persistent epigenomic effects in primary human hepatocytes associated with hepatocellular carcinoma. Toxicology. 350-352:31–39.
   PubMed Web of Science ®Google Scholar
• Rieswijk L, Lizarraga D, Brauers KJJ, Kleinjans JCS, van Delft JHM. 2014. Characterisation of cisplatin-induced transcriptomics responses in primary mouse hepatocytes, HepG2 cells and mouse embryonic stem cells shows conservation of regulating transcription factor networks. Mutagenesis. 29(1):17–26.
   PubMed Web of Science ®Google Scholar
• Rodrigues RM, Heymans A, De Boe V, Sachinidis A, Chaudhari U, Govaere O, Roskams T, Vanhaecke T, Rogiers V, De Kock J, et al. 2016. Toxicogenomics-based prediction of acetaminophen-induced liver injury using human hepatic cell systems. Toxicol Lett. 240(1):50–59.
   PubMed Web of Science ®Google Scholar
• Rodrigues RM, Kollipara L, Chaudhari U, Sachinidis A, Zahedi RP, Sickmann A, Kopp-Schneider A, Jiang X, Keun H, Hengstler J, et al. 2018. Omics-based responses induced by bosentan in human hepatoma HepaRG cell cultures. Arch Toxicol. 92(6):1939–1952.
   PubMed Web of Science ®Google Scholar
• Sarkar U, Ravindra KC, Large E, Young CL, Rivera-Burgos D, Yu J, Cirit M, Hughes DJ, Wishnok JS, Lauffenburger DA, et al. 2017. Integrated assessment of diclofenac biotransformation, pharmacokinetics, and omics-based toxicity in a three-dimensional human liver-immunocompetent coculture system. Drug Metab Dispos. 45(7):855–866.
   PubMed Web of Science ®Google Scholar
• Schwartz RE, Fleming HE, Khetani SR, Bhatia SN. 2014. Pluripotent stem cell-derived hepatocyte-like cells. Biotechnol Adv. 32(2):504–513.
   PubMed Web of Science ®Google Scholar
• Sgro C, Clinard F, Ouazir K, Chanay H, Allard C, Guilleminet C, Lenoir C, Lemoine A, Hillon P. 2002. Incidence of drug-induced hepatic injuries: a French population-based study. Hepatology. 36(2):451–455.
   PubMed Web of Science ®Google Scholar
• Sison-Young RL, Lauschke VM, Johann E, Alexandre E, Antherieu S, Aerts H, Gerets HHJ, Labbe G, Hoët D, Dorau M, et al. 2017. A multicenter assessment of single-cell models aligned to standard measures of cell health for prediction of acute hepatotoxicity. Arch Toxicol. 91(3):1385–1400.
   PubMed Web of Science ®Google Scholar
• Van den Hof WFPM, Coonen MLJ, van Herwijnen M, Brauers K, Wodzig WKWH, van Delft JHM, Kleinjans JCS. 2014. Classification of hepatotoxicants using HepG2 cells: a proof of principle study. Chem Res Toxicol. 27(3):433–442.
   PubMed Web of Science ®Google Scholar
• Van Summeren A, Renes J, Bouwman FG, Noben J-P, van Delft JHM, Kleinjans JCS, Mariman ECM. 2011. Proteomics investigations of drug-induced hepatotoxicity in HepG2 cells. Toxicol Sci. 120(1):109–122.
   PubMed Web of Science ®Google Scholar
• Vorrink SU, Zhou Y, Ingelman-Sundberg M, Lauschke VM. 2018. Prediction of drug-induced hepatotoxicity using long-term stable primary hepatic 3D spheroid cultures in chemically defined conditions. Toxicol Sci. 163(2):655–665.
   PubMed Web of Science ®Google Scholar
• Ware BR, McVay M, Sunada WY, Khetani SR. 2017. Exploring chronic drug effects on microengineered human liver cultures using global gene expression profiling. Toxicol Sci. 157(2):387–398.
   PubMed Web of Science ®Google Scholar
• Watkins PB. 2011. Drug safety sciences and the bottleneck in drug development. Clin Pharmacol Ther. 89(6):788–790.
   PubMed Web of Science ®Google Scholar
• Wilkening S, Stahl F, Bader A. 2003. Comparison of primary human hepatocytes and hepatoma cell line Hepg2 with regard to their biotransformation properties. Drug Metab Dispos. 31(8):1035–1042.
   PubMed Web of Science ®Google Scholar
• Wills LR, Rajagopalan P. 2020. Advances in human induced pluripotent stem cell-derived hepatocytes for use in toxicity testing. Ann Biomed Eng. 48(3):1045–1057.
   PubMed Web of Science ®Google Scholar
• Wolters JEJ, van Breda SGJ, Grossmann J, Fortes C, Caiment F, Kleinjans JCS. 2018. Integrated omics analysis reveals new drug-induced mitochondrial perturbations in human hepatocytes . Toxicol Lett. 289:1–13.
   PubMed Web of Science ®Google Scholar
• Wolters JEJ, van Herwijnen MHM, Theunissen DHJ, Jennen DGJ, Van den Hof WFPM, de Kok TMCM, Schaap FG, van Breda SGJ, Kleinjans JCS. 2016. Integrative “-Omics” analysis in primary human hepatocytes unravels persistent mechanisms of cyclosporine A-induced cholestasis. Chem Res Toxicol. 29(12):2164–2174.
   PubMed Web of Science ®Google Scholar
• Zhou Y, Shen JX, Lauschke VM. 2019. Comprehensive evaluation of organotypic and microphysiological liver models for prediction of drug-induced liver injury. Front Pharmacol. 10:1093.
   PubMed Web of Science ®Google Scholar